Standout Papers

A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, ... 1997 2026 2006 2016 1.6k
  1. A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate (1999)
    Michael E. Weinblatt, Joel M. Kremer et al. New England Journal of Medicine
  2. A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis (2000)
    Joan M. Bathon, Richard W. Martin et al. New England Journal of Medicine
  3. Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein (1997)
    Larry W. Moreland, Scott W. Baumgartner et al. New England Journal of Medicine
  4. Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis (2012)
    Roy Fleischmann, Joel M. Kremer et al. New England Journal of Medicine
  5. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial (2006)
    Paul Emery, Roy Fleischmann et al. Arthritis & Rheumatism
  6. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis (2012)
    Ronald van Vollenhoven, Roy Fleischmann et al. New England Journal of Medicine
  7. Tofacitinib versus Methotrexate in Rheumatoid Arthritis (2014)
    Eun Bong Lee, Roy Fleischmann et al. New England Journal of Medicine
  8. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial (2003)
    John C. Davis, Désirée van der Heijde et al. Arthritis & Rheumatism
  9. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes (2002)
    Mark C. Genovese, Joan M. Bathon et al. Arthritis & Rheumatism
  10. Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study (2013)
    Désirée van der Heijde, Yoshiya Tanaka et al. Arthritis & Rheumatism
  11. Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis (2013)
    Joel M. Kremer, Zhanguo Li et al. Annals of Internal Medicine
  12. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial (2018)
    Mark C. Genovese, Roy Fleischmann et al. The Lancet
  13. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial (2019)
    Roy Fleischmann, Aileen L. Pangan et al. Arthritis & Rheumatology
  14. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment (2016)
    Roy Fleischmann, Michael Schiff et al. Arthritis & Rheumatology
  15. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician (2024)
    Zoltán Szekanecz, Maya H Buch et al. Nature Reviews Rheumatology

Immediate Impact

2 from Science/Nature 142 standout
Sub-graph 1 of 14

Citing Papers

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
2023 Standout
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
2022 Standout

Works of Roy Fleischmann being referenced

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
2018 Standout
Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib
2014

Author Peers

Author Last Decade Papers Cites
Roy Fleischmann 16321 8026 3864 6243 346 22.3k
Joel M. Kremer 14904 6764 3999 4951 323 22.7k
Edward Keystone 16716 7726 4150 6675 400 24.0k
Mark C. Genovese 13775 6345 3494 8351 315 22.2k
Ben A. C. Dijkmans 17930 6033 2068 6125 330 24.4k
Ronald van Vollenhoven 20143 6663 4380 9736 499 26.9k
Daniel Aletaha 14537 5223 2344 4534 318 20.4k
Ferdinand C. Breedveld 14895 5300 2564 5318 179 21.4k
Larry W. Moreland 11918 4910 2323 4650 285 18.4k
Stanley Cohen 10300 4591 2301 4421 212 17.9k
Daniel E. Fürst 12018 5160 2605 4535 252 21.5k

All Works

Loading papers...

Rankless by CCL
2026